While CCR2 and CCR5 receptor antagonists have shown initial promise in pre-clinical studies [14], [15], [27], blockade of CCR2 [16], its ligand CCL2 [31], and CCR5 [17], [18] have failed in clinical trials in RA patients [16]–[18]. The gene discussed is CCL2; the disease is rheumatoid arthritis.